Price (delayed)
$0.128
Market cap
$8.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.84
Enterprise value
-$23.75M
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product
There are no recent dividends present for AGLE.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.